Journal
LEUKEMIA RESEARCH
Volume 35, Issue 9, Pages 1178-1183Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2011.02.009
Keywords
Myeloma; Thalidomide; SNP; DNA repair; Survival; Response
Categories
Funding
- Janssen-Cilag and Celgene
- Fondo de Investigaciones Sanitarias de la Seguridad Social [RD 2006/0020/005, FIS08/0147, CM07/00108]
- Hospital Clinic de Barcelona
Ask authors/readers for more resources
Single nucleotide polymorphisms (SNPs) in 12 genes involving multidrug resistance, drug metabolic pathways, DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma (MM) treated with single agent thalidomide and the results were correlated with response, toxicity and overall survival (OS). The response rate was higher in patients with SNPs in ERCC1 (rs735482) (p = 0.006), ERCC5 (rs17655) (p = 0.04) or XRCC5 (rs1051685) (p = 0.013). Longer OS was associated with the SNP in ERCC1 (rs735482) (p = 0.005) and XRCC5 (rs1051685) (p = 0.02). Finally, polymorphism in GSTT1 (rs4630) was associated with a lower frequency of thalidomide-induced peripheral neuropathy (p = 0.04). (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available